Close Menu


The consortium, led by a Belgium biotech, will use the funds to advance an mRNA-based vaccine as a treatment for head and neck, cervical, and anogenital cancers.

The grant, awarded by the Eurostars program, will support the European companies in their goal of advancing their mRNA-based kidney cancer vaccine.

Based on the promising results, the company is advancing the tumor lysate, particle-loaded, dendritic cell vaccine into Phase III studies.